Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H12O2 |
Molar mass | 176.215 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Centalun was developed by Boehringer Ingelheim in 1962[1] and is a psycholeptic drug with hypnotic and sedative effects, via allosteric agonism of the GABAA receptor.[2] It was previously used for sedation in medical procedures such as surgery,[3] orthopedics[4] and gynecology,[5] although it is no longer in clinical use. Despite its history of clinical use, centalun was never incorporated into the CSA and therefore remains unregulated as a drug of abuse.
Alcohols | |
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|